Contact: Donna Krupa
Office: (301) 634-7209
dkrupa@the-aps.org
Endothelin-Related Drugs Benefit Patients With Pulmonary Hypertension
Can these drugs help with a wider array of diseases? Expert to address conference of experts Being sponsored by the American Physiological Society (APS)
MONTREAL, CN (September 10, 2009) - Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases. The usefulness of the new drugs to treat congestive heart failure is much less clear, said Professor Matthias Barton, M.D. of the Department of Medicine at the University of Zurich School of Medicine.
Dr. Barton will give an update on endothelin research at the American Physiological Society's (APS; www.the-aps.org) 11th International Conference on Endothelin. The title of his talk is "What You Should Know About Endothelin," is part of the symposium, "Roles of Endothelin-1 on Cardiac Function and Diseases." The conference takes place Sept. 9-12 in Montreal.
What is Endothelin?
Endothelin's importance in both health and disease quickly became clear after researchers first discovered its receptors in the early 1990s, according to Dr. Barton. It is the most potent and longest lasting of the blood vessel constrictors (vasoconstrictors) and is 100 times more powerful than the vasoconstrictor norepinephrine.
The human body continuously produces endothelin and increases its production in response to disease conditions, such as inflammation, high blood pressure or high cholesterol. Nitric oxide, a substance also released from the endothelium that dilates the blood vessels (vasodilator), helps counterbalance endothelin production.
Endothelin's duties are wide ranging. In addition to being a vasoconstrictor, it also helps regulate cell growth, contributes to heart muscle contractility and helps determine heart rate. That is only a partial list, and it is all beneficial. On the negative side, endothelin can disturb heart rhythm and promote unfavorable changes in the heart muscle following congestive heart failure. Endothelin also promotes kidney disease and coronary artery disease, among other disorders.
Researchers have recently developed drugs in hopes of blocking the negative effects of the most important form of endothelin, endothelin-1. The drugs, including ambrisentan, bosentan, darusentan, enrasentan, sitaxsentan, and tezosentan are endothelin receptor antagonists. That is, they work by preventing endothelin-1 from linking with one or both of its receptors, ETA and ETB. Endothelin cannot work without at least one of these receptors.
Endothelin Receptor Antagonists and Fighting Disease
Clininal trials have begun to use endothelin receptor antagonists to treat pulmonary hypertension, resistant arterial hypertension, proteinuric renal disease, cancer and autoimmune diseases such as scleroderma. The following are some research highlights on endothelin receptor antagonists:
Pulmonary Hypertension. The FDA has approved the use of endothelin blockers to treat human pulmonary hypertension which is a disease with a poor prognosis. The first clinical trials have demonstrated benefits regarding symptoms and have improved the quality of life of the patients. These drugs targeted either the ETA receptor alone, or both receptors, ETA and ETB, together.
Clinical research so far suggests that endothelin antagonists will be a major part of pulmonary hypertension therapy in the future. Among the issues still to be resolved are whether drugs that block ETA alone will be more effective in treating pulmonary hypertension than drugs that block both ETA and ETB and whether it is best to combine the drugs with other drugs, such as vasodilators.
Proteinuric Renal Disease. Protein excretion in the urine is a reliable predictor of cardiovascular risk. According to the first clinical studies treatment with drugs that block ETA alone, and treatment with drugs that blocks both receptors, reduced protein excretion in the urine in patients with renal failure, even in patients already treated with other anti-proteinuric drugs. Clinical research in this area is ongoing.
Coronary Artery Disease. Research on mice with atherosclerosis (hardening of the arteries from plaque buildup) has found that inhibiting endothelin inhibits the development of atherosclerotic plaque. Also in mice, blocking the ETA receptor alleviates some of the causes leading to angina and can reduce damage to the heart tissue following a heart attack. Finally, chronic treatment with an ETA receptor improves the ability of blood vessels to dilate. This improved vasodilation has also been found in human studies.
Resistant Arterial hypertension. Treatment with a drug that blocks ETA alone, and treatment with a drug that blocks both receptors, substantially reduced arterial blood pressure in human patients with essential or resistant essential hypertension. Further research is necessary to determine whether the drugs can reduce hypertension-related organ damage such as failure of the heart or kidneys or the number of deaths associated with hypertension.
Heart Failure. In several long-term clinical studies with human patients with acute or chronic congestive heart failure, none has shown that the receptor blockers can provide any benefit. Dr. Barton noted that not all of the data from the human trials was available to scientists so that they could further analyze these results. In addition, patients in the trials received the endothelin blockers along with standard treatments for heart failure, perhaps masking the possible benefits of the new drugs, he said. He recommends further research in the area of heart failure, which could possibly include lower drug dosages and close monitoring and treatment of edema in this very ill patient population.
*********
Editor's Notes: To arrange an interview with Dr. Barton, please contact Donna Krupa (301) 634-7209 or at dkrupa@the-aps.org.
Physiology is the study of how molecules, cells, tissues and organs function to create health or disease. The American Physiological Society (APS) has been an integral part of this scientific discovery process since it was established in 1887.
Leading Expert Examines Status, Promise of Key Human Protein - Endothelin - at APS Conference
Released September 10, 2009 - As the scientific and medical communities involved in endothelin move towards 25 years of understanding the protein, which future developments hold potential? At what risk? Do medicinal compounds look promising? These are among the topics being discussed at the American Physiological Society's 11th International Conference on Endothelin.
Males May Experience Greater Physical Pain Due to Lower Levels of Key Protein, Endothelin
Released September 10, 2009 - How vaso-occulsion leads to pain, and its impact on males and females are still unknown. A University of South Carolina research team suggests that a naturally occurring chemical in the body, endothelin, may play a role. Presentation is part of the American Physiological Society's 11th International Conference on Endothelin.
A Simple Way for Middle Aged & Older Adults to Assess How Stiff Their Arteries Are: Reach for their Toes
Released October 6, 2009 - How far you can reach beyond your toes from a sitting position - normally used to define the flexibility of a person's body - may be an indicator of how stiff your arteries are.
Brown Rice and Cardiovascular Protection
Released April 26, 2010 -- Brown rice might have an advantage over white rice by offering protection from high blood pressure and atherosclerosis (“hardening of the arteries”), say researchers at Temple University School of Medicine in Philadelphia. New research suggests that a component in a layer of tissue surrounding grains of brown rice may work against angiotensin II, an endocrine protein and a known culprit in the development of high blood pressure and atherosclerosis.
Macrophages: The “Defense” Cells That Help Throughout the Body
Released August 26, 2010 - Microphages are antimicrobial warriors and play critical roles in immune regulation and wound-healing. They can respond to a variety of cellular signals and change their physiology in response to local cues. This presentation focused on how macrophages exist in nearly all tissues and are produced when white blood cells called monocytes leave the blood and differentiate in a tissue-specific manner. Immune-regulating macrophages produce high levels of the cytokine interleukin-10, which helps suppress the body’s immune response and may hold the key to developing treatments for autoimmune diseases such as multiple sclerosis or rheumatoid arthritis.